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Abstract: The current study examined and compared the willingness of young Black men
who have sex with men (YBMSM) to accept pre-exposure prophylaxis (PrEP), adult male
circumcision, and condoms for reducing their risk of HIV acquisition. The majority (67%)
reported unprotected receptive anal sex in the last six months. About three-quarters (71%)
would accept using PrEP if it was 100% effective. Cost influenced PrEP acceptance with
19% indicating acceptance at $100 per month co-pay. Of those not circumcised, 50%
indicated willingness if circumcision was 100% effective. Acceptance of circumcision
decreased markedly to 17% with co-pays of $100. About 73% of men were willing to use
condoms if they were 100% effective and 50% indicated a willingness at the cost of $10
per month. The findings suggest that condom use promotion strategies should remain at the
forefront of public health efforts to control HIV incidence among YBMSM.
Keywords: African American men who have sex with men; HIV/AIDS; condoms; PrEP;
circumcision
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1. Introduction
The southern region of the United States comprises the largest percentage (18%) of Black
Americans and accounts for 46% of all new HIV diagnoses and more than 55% of HIV prevalence [1].
Young Black men who have sex with men (YBMSM) represent 73% of HIV incidence among all
Black men and 37% of all MSM [2,3]. YBMSM aged 13–29 years are the only subgroup to have
experienced a continuous increase in HIV incidence rates during the last three years [4]. Based on
these marked racial/ethnic disparities, many questions remain about the acceptance of newly
developed as well as established HIV prevention strategies for YBMSM.
The use and effectiveness of condoms against HIV and other sexually transmitted infections (STI)
are empirically supported, showing a 59% decrease in STI acquisition with accurate and consistent
condom utilization [5–9]. Despite this effectiveness, continued disparities have increased the need for
additional approaches to HIV prevention [10]. In recent years, biomedical strategies have reemerged as
promising efforts in this regard.
Pre-exposure prophylaxis (PrEP) is an empirically supported antiretroviral medication consumed
prior to HIV exposure to prevent potential acquisition [11]. Results from the PrEP Initiative study
showed a 44% reduction in HIV risk transmission among MSM and eventually led to the release of
federal guidelines and FDA approval for PrEP as an HIV prevention strategy [12–14]. PrEP acceptability
has varied between 30% and 80% [15–17] and its uptake has been influenced by demographic
characteristics (e.g., age and education), sexual risk behavior and perception of risk [18,19].
Another biomedical strategy is adult male circumcision [20,21], which has been recommended as
part of a comprehensive approach to HIV prevention [22]. However, effectiveness data have varied
among MSM [23–25] with a paucity of data specific to Black MSM [26,27].
The continued increase of HIV in YBMSM has created a need to understand what prevention
strategies are most acceptable to this population. Therefore, the purpose of this study was to describe
the willingness of YBMSM to accept the use of condoms, PrEP, and circumcision for reducing their
risk of HIV acquisition.
2. Methods
Participants were recruited between 15 January 2013 and 14 February 2013, through banner
advertisements on the Black Gay Chat website. These advertisements were restricted to residents of
Mississippi, Louisiana, Alabama and Georgia. Website visitors who clicked on a banner ad were
redirected to the internet-survey for completion. The survey was developed through the Qualtrics
online system and included no accessibility limitations (i.e., desktop or mobile preferences). Young
men were eligible if they had sex with a man in the past six months, were 18–39 years of age, and
identified as being African American or Black. Incentives were not provided. The survey was
anonymous and assessed questions assessing demographics, sexual risk behavior and determinants in
the utilization of HIV prevention methods. The Institutional Review Board at the University of
Kentucky approved all study protocols. Data were analyzed using frequency distributions.
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3. Results
The sample consisted of young Black men who have sex with men (YBMSM) (N = 95), ages 18–39
years (mean = 26.8, SD = 5.66). In the last six months, 72% reported insertive anal sex and 74%
reported receptive anal sex. The majority (71%) reported engaging in at least one act of anal sex that
was not condom-protected. During the last six months, 67% reported at least one instance of engaging
in unprotected receptive anal sex and 56% reported engaging in one instance of unprotected insertive
anal sex (See Table 1).
Table 1. Characteristics of the Study Sample, African American Men, Aged 18–39 (N = 95).
Variable
Age
Anal insertive (top) sex
Yes
No
Anal insertive (top) sex
with a condom
Yes
No
Anal insertive (top) sex
without a condom
Yes
No
Anal receptive (bottom) sex
Yes
No
Anal receptive (bottom) sex
with a condom
Yes
No
Anal receptive (bottom) sex
without a condom
Yes
No

Mean (SD)
26.8 (5.66)

n (%)

68 (71.6)
27 (28.4)

50 (86.2)
8 (13.8)

33 (55.9)
26 (44.1)
70 (73.7)
25 (26.3)

49 (79.0)
13 (21.0)

42 (66.7)
21 (33.3)

Nearly three-quarters (71%) of the men were willing to accept PrEP if it was 100% effective.
Willingness to accept this method decreased with a lower level of effectiveness: 75% effectiveness
(43%) and 50% effectiveness (21%). Cost had an influence on men’s willingness to accept PrEP: 19%
were willing to accept the medication with a personal cost of $100. Table 2 provides greater details.
The majority (75%) of the participants were circumcised. Of those young men who were not
circumcised (n = 24), 50% indicated a willingness to be circumcised if this procedure was 100%
effective in avoiding HIV infection. Acceptance of circumcision as an HIV prevention strategy
decreased markedly to 17% with a personal cost of $100. Table 3 provides more information regarding
the decline in acceptance based on cost and effectiveness.

Vaccines 2014, 2

132

Table 2. Acceptance of pre-exposure prophylaxis (PrEP) as a Safe Sex Measure (N = 95).
Variable
PrEP acceptance based on 100% effectiveness against HIV
Yes
No
PrEP acceptance based on 75% effectiveness against HIV
Yes
No
PrEP acceptance based on 50% effectiveness against HIV
Yes
No
PrEP acceptance based on cost-Free
Yes
No
PrEP acceptance based on cost-$100 or less per month
Yes
No
PrEP acceptance based on cost-$500 per month
Yes
No
PrEP acceptance based on cost-$1000 per month
Yes
No

n (%)
67 (70.5)
28 (29.5)
41 (43.2)
54 (56.8)
20 (21.1)
74 (77.9)
58 (61.1)
36 (37.9)
18 (18.9)
77 (81.1)
16 (16.8)
77 (81.1)
13 (13.7)
82 (86.3)

Table 3. Acceptance of Circumcision as a Safe Sex Measure (N = 24).
Variable
Circumcised
Yes
No
Circumcision acceptance based on 100% effectiveness against HIV
Yes
No
Circumcision acceptance based on 75% effectiveness against HIV
Yes
No
Circumcision acceptance based on 50% or less effectiveness
against HIV
Yes
No
Circumcision acceptance based on cost-Free
Yes
No
Circumcision acceptance based on cost-$100 or less
Yes
No
Circumcision acceptance based on cost-$500 or more
Yes
No

n (%)
71 (74.7)
24 (25.3)
12 (50.0)
12 (50.0)
9 (37.5)
15 (62.5)

8 (33.3)
16 (66.7)
13 (54.2)
11 (45.8)
4 (16.7)
20 (83.3)
1 (4.2)
23 (95.8)
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The majority of the men (73%) were willing to use condoms if they were 100% effective, with 50%
indicating this willingness to accept this prevention strategy at a cost of $10 per month. Table 4
provides greater detail about these findings.
Table 4. Acceptance of condoms as a safe sex measure (N = 95).
Variable
Condom acceptance based on 100% effectiveness against HIV
Yes
No
Condom acceptance based on 75% effectiveness against HIV
Yes
No
Condom acceptance based on 50% or less effectiveness against HIV
Yes
No
Condom/Lubricant acceptance based on cost-Free
Yes
No
Condom/Lubricant acceptance based on cost-$10 per month
Yes
No
Condom/Lubricant acceptance based on cost-$100 per month
Yes
No

n (%)
69 (72.6)
26 (27.4)
57 (60.0)
38 (40.0)
40 (42.1)
55 (57.9)
64 (67.4)
31 (32.6)
47 (49.5)
48 (50.5)
18 (18.9)
77 (81.1)

4. Discussion
Regardless of the HIV prevention method being offered, small personal costs have a substantial
adverse influence on acceptance of PrEP, circumcision or condom use. Generally, the level of
acceptance for all three methods was low, unless the method was rated at 100% efficacy and provided
at minimal cost to the participant. The findings suggest that even under ideal circumstances (100%
effective and free) a large proportion of men may not be willing to use any of these methods. This
observation led to a post-hoc analysis that calculated the percent of men who would not accept the
method even under both ideal circumstances (100% efficacy and free). This analysis was achieved
through the use of a contingency table. These findings showed that 27% would not accept PrEP, 42%
of those not circumcised would refuse do so, and 21% would not use condoms. These values are high
given that the ideal circumstances are unlikely to exist, with the possible exception of condom use.
Findings regarding PrEP are particular intriguing. The current findings are similar to those from
other studies that examined barriers to PrEP acceptance [18]. Previous studies have shown that
government funding to assist in the accessibility of PrEP could be a facilitator to the acceptance of this
HIV prevention method [18]. Cost-effectiveness has been one of the primary considerations in the use
of public funds for these prevention strategies. Delivery of PrEP was found to be a cost-effective
strategy for high-risk populations [28,29], but acceptance among YBMSM may alter this equation.
Resources to assist in subsidizing personal costs to YBMSM may be needed to enhance uptake of
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these prevention strategies [30]. PrEP effectiveness has been established from clinical trials when
combined with condom use, HIV testing and other established prevention methods [15,30,31]. Although
the current evidence supports this strategy, further research is needed regarding whether YBMSM most
at-risk of HIV will indeed seek out a provider to give them PrEP at a price they can afford.
5. Limitations
These findings are limited based on the validity of self-reported data. The participants were a
sample of men who opted into an online banner-ad survey and therefore the findings are subject to
selection bias. Convenience sampling and restrictions to the southern region of the U.S. limits the
generalizability of the findings to other populations of MSM. The results are based on a small sample
size and therefore further research is warranted. Additionally, the findings provide limited insight to
the participants’ knowledge of HIV prevention methods. This information could be a facilitator or barrier
to their decision to prefer certain safe sex methods and should be further examined in future research.
6. Conclusions
Biomedical approaches to HIV prevention, such as the use of PrEP and circumcision, will
ultimately require patient acceptance. Availability alone may not be an adequate response. Given
optimal circumstances (i.e., 100% effective and no personal costs) PrEP and circumcision are less
acceptable to YBMSM than condom use. Because these optimal circumstances may never exist,
findings suggest that condom use promotion strategies should remain at the forefront of public health
efforts to control HIV incidence among YBMSM. Further, the study findings suggest that HIV
preventive measures offered to YBMSM may not be widely embraced, including condom use. Apathy
about preventing HIV infection may be a barrier working against efforts to innovatively protect this
population. Thus, the role of behavioral science in HIV prevention is one that can complement and
enhance emergent biomedical strategies.
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